:


Attal M,etal. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349:2495.

Barlogie B, et al. Treatment of multiple myeloma. Blood 2004; 103:20.

Bensiger WI, Maloney D, Storb R. Allogeneic hematopoietic cell transplantation for multiple myeloma. Semin Hematol 2001; 38:243.

Berenson JR. Etiology of multiple myeloma: what's new. Semin Oncol 1999; 26 (Suppl 13, October):2.

Berenson J R, Crowley JJ, Grogan TM. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163.

Berenson J R, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16:593.

Berenson J R, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 91:1191.

Child JA, et al. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. TV Engl J Med 2003; 348:1875.

Dimopoulos MA, et al. Treatment of plasma cell dyscrasias with thalidomide and its derivatives. J Clin Oncol 2003; 21:4444.

Fonseca R, et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101:4569.

Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78:21.

Lauta VM. A review of the cytokine network in multiple myeloma. Cancer 2003; 97:2440.

Magrangeas F, et al. Gene expression profiling of multiple myeloma reveals molecular portraits in relation to the pathogenesis of the disease. Blood 2003; 101:4998.

Maloney DG, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102:3447.

Rajkumar SV, et al. Thalidomide as initial therapy for early- stage myeloma. Leukemia 2003; 17:775.

Richardson PG, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348:2609.

Seidl S, Kaufmann H, Drach J. New insights into the pathophysiology of multiple myeloma. Lancet Oncol 2003; 4:557.

Seldin DC, et al. Tolerability and efficacy of thalidomide for the treatment of patients with light chain-associated (AL) amyloidosis. Clin Lymphoma 2003; 3:241.

Sezer O, et al. RAN ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101:2094.

Tian E, et al. The role of the Wnt-signaling antagonist DKK.1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349:2483.

Treon SP, et al. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia. J Immunother 2001; 24:272.

Weber D, et al. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21:16.

Wu K-D, et al. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 2003; 101:4982.

Zent CS, et al. The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. Leuk Res 2003; 27:765.

: